PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2013 | 3 | 2 | 104-107
Article title

Rola lapatynibu w leczeniu HER2-dodatniego raka piersi

Content
Title variants
EN
The role of lapatinib in HER2-positive breast cancer
Languages of publication
PL
Abstracts
EN
HER2 positive breast cancer presents 25–35% of newly diagnosed cases and is associated with more aggressiveness and poorer prognosis. The anti-HER2 monoclonal antibody trastuzumab improved the outcome of women with HER positive breast cancer. Despite the primary effectiveness resistance to trastuzumab occurs. The second drug which interacts with HER2 receptor is lapatinib. There is no cross resistance between both drugs. Lapatinib is dual, reversible tyrosin kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor type 2 (HER2). Based on the results of the clinical trials the efficacy and safety of lapatinib was confirmed.
PL
Rak piersi z nadekspresją receptora HER2 lub amplifikacją jego genu stanowi ok. 25–30% zachorowań i wiąże się z bardziej agresywnym przebiegiem i gorszym rokowaniem. Wprowadzenie trastuzumabu – pierwszego leku celowanego ukierunkowanego na zewnątrzkomórkową domenę receptora HER2 – poprawiło skuteczność leczenia. Mimo pierwotnej odpowiedzi na leczenie dochodzi do wytworzenia oporności i progresji choroby. Drugim lekiem wpływającym na receptor HER2 jest lapatynib. Nie stwierdzono krzyżowej oporności między obydwoma lekami. Lapatynib to odwracalny inhibitor kinazy tyrozynowej dwóch receptorów EGFR i HER2. Na podstawie badań klinicznych udowodniono jego skuteczność i bezpieczeństwo w leczeniu HER2-dodatniego raka piersi.
Keywords
Discipline
Publisher
Journal
Year
Volume
3
Issue
2
Pages
104-107
Physical description
References
  • Slamon D., Clark G., Wong S. et al.: Human Brest cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 1987; 235: 177-82.
  • Dawood S., Broglio K., Buzdar A.U.: Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J. Clin. Oncol. 2010; 28: 92-8.
  • Liu L., Greger J., Shi H. et al.: Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res. 2009; 69: 6871-6878.
  • Lackey K.: Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor. Curr. Top. Med. Chem. 2006; 23: 2502-2512.
  • Geyer C., Forster J., Lindquist D. et al.: Lapatinib plus capecytabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 2006; 355: 2733-2743.
  • Cameron D., Casey M., Press M. et al.: Phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res. Treat. 2008; 112: 533-543.
  • Cameron D., Casey M., Olivia C. et al.: Lapatinib plus capecytabine in women with HER2-positive advanced breast cancer: final results analysis of a phase III randomized trial. Oncologist 2012; 15: 924-934.
  • Zhou X., Cella D., Cameron D. et al.: Lapatinib plus capecytabine versus capecytabine alone for HER2 metastatic breast cancer: quality of life assessment. Breast Cancer Res. Treat. 2009; 117: 577-589.
  • Johnston S., Pippen J., Pivot X. et al.: Lapatinib combined with letrozol versus letrozol and placebo as first line therapy for postmenopausal hormone-receptor-positive metastatic breast cancer. J. Clin. Oncol. 2009; 27: 5538-5546.
  • Stemmler H.J., Kahlert S., Siekiera W. et al.: Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 2006; 15: 219-25.
  • Yau T., Swanton C., Chua S. et al.: Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol. 2006; 45: 196-201.
  • Bachelot T.D. et al.: LANDSCAPE: an FNCLCC phase II study with lapatinib (L) and capecitabine (C) in patients with brain metastases (BM) from HER2-positive (+) metastatic breast cancer (MBC) before whole-brain radiotherapy (WBR). J. Clin. Oncol. 2011; 29(suppl.):509.
  • Capri G., Chang J., Chen S. et al.: An open-label expanded access study of lapatinib and capecytabine in patients with HER2-overexpressing locally advanced or metastatic braest cancer. Ann. Oncol. 2010; 21: 474-480.
  • Metro G., Foglietta J., Russillo M. et al.: Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann. Oncol. 2011; 22: 625-630.
  • Congress: ESMO 2012, Abstract: 3778. CEREBEL (EGF111438): An open label randomized phase III study comparing the incidence of CNS metastases in patients (pts) with HER2+ Metastatic Breast Cancer (MBC), treated with Lapatinib plus Capecitabine (LC) versus Trastuzumab plus Capecitabine (TC).
  • Valachis A., Mauri D., Polyzos N. et al.: Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis. Breast 2011; 20: 485-490.
  • Baselga J., Bradbury I., Eidtmann H. et al.: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012; 379: 633-40.
  • Valachis A., Nearchou A., Lind P. et al.: Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence. Breast Cancer Res. Treat. 2012; 135: 655-662.
  • Huang Z., Brdlik C., Jin P. et al. A pan-HER approach for cancer therapy: background, current status and future development. Expert Opin. Biol. Ther. 2009; 9: 97-110.
Document Type
article
Publication order reference
YADDA identifier
bwmeta1.element.psjd-fd034547-1399-4870-b90e-d9416a681d7a
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.